Oculeve
Acquired
- Headquarters
- San Francisco
- Founded
- 2011
- Business Model
- B2B
- Last Round
- Series BMar 2014
About
Oculeve was a medical device company that developed TrueTear, a first-in-class non-invasive nasal neurostimulation device that activates the nasolacrimal pathway to stimulate natural tear production in patients with dry eye disease. Founded out of Stanford Biodesign, the company raised $24M before being acquired by Allergan in 2015 for $125 million upfront. The TrueTear device received FDA clearance and commercialized under Allergan.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account